Hanmi Pharm Terminates Belvarafenib Licensing Agreement... Genentech Returns Rights
Genentech Issues Notice of Termination; Agreement Ends on December 27
Hanmi Pharm Will Keep the 80 Million Dollar Upfront Payment
Genentech, which had licensed Hanmi Pharmaceutical's investigational new drug candidate "Belvarafenib" in 2016, has returned the rights to the drug after about ten years.
On September 29, Hanmi Pharmaceutical announced that it had received a formal notice from Genentech regarding the termination of the technology transfer agreement and the return of rights for Belvarafenib.
Hanmi Pharmaceutical and Genentech signed a technology transfer agreement for the oral targeted anticancer drug Belvarafenib on September 28, 2016. The deal was valued at a total of $910 million (approximately KRW 1.234 trillion), which included an upfront payment of $80 million (approximately KRW 108.5 billion).
With the termination of the agreement, Hanmi Pharmaceutical regains the rights to Belvarafenib from Genentech. The upfront payment of $80 million received from Genentech will not be returned.
A Hanmi Pharmaceutical representative stated, "This disclosure is the 'contractual closure procedure' for the matter that Genentech had already formalized several years ago by announcing it would cease development, and it was an anticipated outcome." The official added, "Currently, Hanmi is smoothly conducting a Phase 2 clinical trial in Korea of Belvarafenib as an oral anticancer therapy for malignant melanoma."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hanmi Pharmaceutical also plans to further strengthen its development partnership with Genentech for its obesity treatment candidate HM17321, which was out-licensed in September this year for up to $2.3 billion (approximately KRW 3.1723 trillion).
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.